Effects of topiramate on oral dyskinesia induced by reserpine

Página do item simplificado
dc.contributor.authorAraujo, N. P.
dc.contributor.authorAbilio, V. C.
dc.contributor.authorSilva, R. H.
dc.contributor.authorPereira, R. C.
dc.contributor.authorCarvalho, R. C.
dc.contributor.authorGonzalez, C.
dc.contributor.authorBellot, R. G.
dc.contributor.authorCastro, JPMV
dc.contributor.authorFukushiro, D. F.
dc.contributor.authorRodrigues, MSD
dc.contributor.authorChinen, C. C.
dc.contributor.authorFrussa, R.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:37:31Z
dc.date.available2016-01-24T12:37:31Z
dc.date.issued2004-12-15
dc.description.abstractRecently, we have described the antidyskinetic property of the GABA mimetic drug valproic acid on reserpine-induced oral dyskinesia, an animal model that has been related to tardive as well as acute dyskinesias, which are associated with important neuropathologies. the present study investigates the effects of different doses of the GABA mimetic anticonvulsant topiramate on the manifestation of reserpine-induced orofacial dyskinesia. Female EPM-M1 mice received two injections of control solution or of 0.5 mg/kg reserpine separated by 48 h. Twenty-four hours after the second reserpine or control solution injection, animals were acutely treated with control solution or topiramate (1, 3, 10 or 30 mg/kg) and were observed for quantification of oral dyskinesia or general activity in an open-field. in order to verify the effects of topiramate per se on oral dyskinesia or general activity, female EPM-M1 mice were acutely treated with control solution or 1, 3, 10 or 30 mg/kg topiramate and observed for quantification of oral dyskinesia and general activity. the highest dose of topiramate completely abolished the manifestation of reserpine-induced oral dyskinesia whereas the doses of 3 and 10 mg/kg significantly attenuated it. None of the doses of the anticonvulsant modified spontaneous locomotion frequency or oral movements, whereas spontaneous rearing frequency was decreased by 3, 10 and 30 mg/kg topiramate. the highest dose of topiramate did not modify general activity in reserpine-treated mice. These results support the potential therapeutic use of topiramate in the treatment of oral dyskinesias. (C) 2004 Elsevier Inc. All rights reserved.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, BR-04023062 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, BR-04023062 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent331-337
dc.identifierhttp://dx.doi.org/10.1016/j.brainresbull.2004.09.001
dc.identifier.citationBrain Research Bulletin. Oxford: Pergamon-Elsevier B.V., v. 64, n. 4, p. 331-337, 2004.
dc.identifier.doi10.1016/j.brainresbull.2004.09.001
dc.identifier.issn0361-9230
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28051
dc.identifier.wosWOS:000225601200007
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofBrain Research Bulletin
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectanticonvulsanten
dc.subjectGABAen
dc.subjectmovement disordersen
dc.subjectmiceen
dc.titleEffects of topiramate on oral dyskinesia induced by reserpineen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral